Freenome, Inc. (FRNM)
Healthcare · NGM
Fundamentals
Valuation and ratings
Freenome, Inc. trades at USD11.24. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
Our moat model scores it 9 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
About Freenome, Inc.
Freenome, Inc. operates as a biotechnology company focused on developing blood-based tests for early cancer detection using artificial intelligence and multiomics technology. The company develops and provides blood-based tests for early cancer detection, including a test for colorectal cancer screening. It offers a multiomics platform that combines computational biology, machine learning, and multiple data types to identify biomarkers and detect various cancers. The company conducts clinical research programs, such as the PREEMPT CRC, Sanderson, and Vallania studies, to validate and expand its cancer detection tests to multiple cancer types. It collaborates with healthcare organizations and partners to advance clinical studies and enhance its product portfolio, including an autoantibody platform with additional biomarkers, and provides patient stratification and monitoring solutions using its multiomics technology. The company was founded in 2014 and is based in Brisbane, California.
FRNM passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
The full research page for FRNM, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.